AccessMyLibrary provides FREE access to millions of articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
Gilead announces 144-week data of Hepsera in patients co-infected with HIV and lamivudine-resistant HBV.
(From Chemical Business NewsBase - Press Release)
Gilead Sciences announced that treatment with its once-daily, oral antiviral agent Hepsera (adefovir dipivoxil 10 mg) was associated with sustained reductions in levels of hepatitis B virus (HBV) DNA through 144 weeks among patients chronically infected with lamivudine-resistant HBV and co-infected with HIV. Data from the single-centre, open-label clinical trial (Study 460i) were presented at the 54th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Boston, MA. Study 460i is a single-centre, open-label study of Hepsera in chronic hepatitis B patients with lamivudine-resistant HBV and …
